New Strategies Promise Better Diagnosis, Treatment For Prostate Cancer

May 13, 1996

STANFORD -- More than two-thirds of the men who test positive on the prostate-specific antigen (PSA) test don't have cancer but they have to undergo a needle biopsy of the prostate to find out for sure. Now, researchers have taken the first step toward eliminating the need for most of those biopsies.

The group, led by Stanford urology professor Dr. Thomas Stamey, will describe potential ways to reduce the PSA test's false-positive rate on Tuesday, May 7 at the American Urological Association's annual meeting, in Orlando, Fla.

Generally, a PSA level greater than 4 billionths of a gram per milliliter of blood is considered suggestive of prostate cancer. However, 68 percent of men with PSA levels greater than 4 do not have cancer, said Stamey. He estimates that at least 90 percent of these false positives are due to benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate.

The most striking and cost-effective prospect for reducing false positives hinges on an identifying characteristic of BPH, Stamey's team reports. Normally, prostate-specific antigen is found in semen, but Dr. John McNeal, a clinical senior research scientist at Stanford University School of Medicine discovered a way to extract PSA directly from the prostate enlargements caused by BPH. Senior research associate Dr. Zuxiong Chen isolated this PSA, purified it and showed that it differs from most of the PSA found in semen.

"The PSA protein for BPH is similar to regular PSA, but there is a cleavage inside the molecule. It's nicked," said Chen, lead author of the BPH PSA research report. "It's not an intact molecule; a disulfide bond links it together."

The next step for the Stanford researchers will be to inject the newly isolated PSA into a mouse to try to obtain a monoclonal antibody against the substance. If the Stanford group is successful, this will yield a new PSA test that can distinguish cases in which high PSA levels are due to benign prostate enlargement rather than cancer, Stamey said.

"Men with BPH would not have to be biopsied if we could identify them on the PSA test," Stamey said.

Chen's paper is one of 10 the Stanford team will present at this week's meeting.

In another study, the team used a computer to analyze combined results from five prostate cancer markers in addition to PSA. Using this method as a diagnostic aid reduced the false-positive rate from 68 percent to 15 percent, reports Stamey.

Other studies focused on developing better treatment strategies. For example, complete removal of the prostate gland fails to eliminate the cancer in about 38 percent of cases, Stamey said. Researchers led by Dr. Michael Gong, chief resident in urology at Stanford University Hospital, found that while subsequent radiation treatments apparently could cure about 28 percent of these men with residual cancer, the apparent cure rate jumped to 71 percent when radiation treatments were combined with six months of combined androgen deprivation therapy.

Another study looked at men with prostate cancers larger than 12 cubic centimeters. Stamey's group was able to identify prognostic markers for deciding whether or not these men were likely to benefit from surgery to remove the tumor. Surgery eliminates the cancer in only 3 to 6 percent of such patients, Stamey said. Using information from the PSA test, digital rectal examinations, and prostate biopsies, Dr. Gregory Cost, a resident at Stanford University Hospital, put together a prediction model identifying 86 percent of those who would not benefit from prostate surgery.

"All of these [new papers] are interrelated," Stamey said. "We are trying to improve the diagnosis of prostate cancer and the ability to decide who should be treated and who should not."
-end-


Stanford University Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.